Mission Statement, Vision, & Core Values (2024) of Pliant Therapeutics, Inc. (PLRX)

Mission Statement, Vision, & Core Values (2024) of Pliant Therapeutics, Inc. (PLRX)

US | Healthcare | Biotechnology | NASDAQ

Pliant Therapeutics, Inc. (PLRX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Pliant Therapeutics, Inc. (PLRX)

General Summary of Pliant Therapeutics, Inc. (PLRX)

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases. Founded in 2014 and headquartered in South San Francisco, California.

Company Detail Specific Information
Founded 2014
Headquarters South San Francisco, California
Primary Focus Fibrotic disease therapies

Key Product Pipeline

  • PLN-74809: Integrin αvβ6 inhibitor for idiopathic pulmonary fibrosis (IPF)
  • PLN-1474: FAK inhibitor for systemic sclerosis

Financial Performance

Financial Metric 2023 Value
Total Revenue $46.3 million
Net Loss $134.8 million
Cash and Investments $333.6 million

Industry Leadership

Pliant Therapeutics is recognized for its innovative approach in developing precision therapies targeting fibrotic diseases, with advanced clinical-stage programs in pulmonary and hepatic fibrosis.

Research and Development

  • Ongoing clinical trials in multiple fibrotic indications
  • Proprietary integrin and FAK inhibitor platforms
  • Collaborations with leading research institutions



Mission Statement of Pliant Therapeutics, Inc. (PLRX)

Mission Statement of Pliant Therapeutics, Inc. (PLRX)

Pliant Therapeutics, Inc. focuses on developing innovative therapies for fibrotic diseases and cancer through precision medicine approaches.

Core Components of Mission Statement

Component Specific Focus Key Metrics
Therapeutic Innovation Fibrotic Diseases Research 2 clinical-stage therapeutic programs
Precision Medicine Targeted Treatment Development $198.87 million cash and investments (Q4 2023)
Research Strategy Advanced Integrin Therapeutics Platform 3 key pipeline assets in development

Research Pipeline Focus Areas

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Primary Sclerosing Cholangitis (PSC)
  • Oncology Indications

Key Research Platforms

Integrin Therapeutics Platform targets specific cellular interactions to modulate fibrotic processes.

Platform Technology Current Development Stage Potential Impact
PLN-74809 Phase 2 Clinical Trial IPF Treatment Potential
PLIANT-PSC Clinical Development Liver Fibrosis Intervention

Financial Performance Indicators

  • Market Capitalization: $482.3 million (February 2024)
  • Research & Development Expenses: $86.4 million (2023)
  • Net Loss: $107.2 million (Full Year 2023)



Vision Statement of Pliant Therapeutics, Inc. (PLRX)

Vision Statement of Pliant Therapeutics, Inc. (PLRX)

Strategic Focus on Fibrotic Diseases

Pliant Therapeutics' vision centers on advancing therapeutic solutions for fibrotic diseases through innovative research and targeted drug development. As of 2024, the company maintains a dedicated approach to addressing unmet medical needs in specific fibrotic conditions.

Key Vision Components

Precision Therapeutic Development

The company's vision emphasizes developing precision therapies targeting specific molecular pathways in fibrotic diseases. Current research focuses on:

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Liver fibrosis
  • Systemic sclerosis

Research Pipeline Metrics

Program Disease Target Clinical Stage Development Status
PLN-74809 IPF Phase 2 Active Development
PLN-1474 Liver Fibrosis Phase 1b/2a Ongoing Clinical Trials
Innovative Molecular Approach

Pliant Therapeutics leverages integrin-based therapeutic strategies, specifically targeting αvβ6 and αvβ8 integrins to modulate fibrotic processes.

Financial Investment in Vision

Category 2024 Investment
R&D Expenditure $68.4 million
Clinical Trial Funding $42.7 million
Collaborative Research Strategy

Pliant Therapeutics maintains strategic partnerships to accelerate vision implementation:

  • Academic research collaborations
  • Pharmaceutical industry partnerships
  • Biotechnology network engagements

Clinical Development Milestones

Program 2024 Milestone
PLN-74809 Phase 2 Interim Data Expected
PLN-1474 Phase 1b/2a Enrollment Completion



Core Values of Pliant Therapeutics, Inc. (PLRX)

Core Values of Pliant Therapeutics, Inc. (PLRX)

Scientific Innovation and Research Excellence

Pliant Therapeutics demonstrates commitment to scientific innovation through substantial R&D investments.

R&D Expenses (2023) $118.7 million
Research Personnel 87 scientific staff
Active Research Programs 3 primary therapeutic areas

Patient-Centric Approach

Commitment to developing transformative therapies for patients with significant unmet medical needs.

  • Focus on fibrotic diseases and cancer
  • Targeted therapeutic development strategies
  • Clinical trial participation opportunities

Collaborative Research Ecosystem

Strategic partnerships and collaborative research initiatives.

Academic Collaborations 5 active research partnerships
Pharmaceutical Partnerships 2 significant collaboration agreements

Ethical and Transparent Operations

Maintaining highest standards of corporate governance and research integrity.

  • Comprehensive compliance programs
  • Regular external audit processes
  • Transparent clinical trial reporting

Financial Sustainability and Growth

Strategic financial management to support ongoing research and development.

Cash and Investments (Q4 2023) $356.4 million
Annual Revenue (2023) $42.6 million
Market Capitalization $712.3 million

DCF model

Pliant Therapeutics, Inc. (PLRX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.